Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» AP30663
AP30663
Acesion, targeting first new approach to AF in decades, hits primary endpoint in midphase trial
Acesion, targeting first new approach to AF in decades, hits primary endpoint in midphase trial
Fierce Biotech
Acesion Pharma
atrial fibrillation
clinical trials
AP30663
Flag link:
